Evolving role of platelet function testing in coronary artery interventions

Rakesh K Sharma 1
Donald J Voelker 1
Rohit Sharma 1
Hanumanth K Reddy 1
Harvinder Dod 1
James D Marsh 2

1 Medical Center of South Arkansas, 2 Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Abstract: The substantial reduction in ischemic events provided by the dual antiplatelet regimen with aspirin and clopidogrel is well documented in patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention. Recently the variable response to the antiplatelet agents has received considerable attention after several “boxed warnings” on clopidogrel. This led to intense controversy on pharmacokinetic, pharmacodynamic, and pharmacogenomic issues of antiplatelet drugs, especially clopidogrel. Research use of platelet function testing has been successfully validated in identifying new antiplatelet drugs like prasugrel and ticagrelor. These platelet function assays are no longer regarded just as a laboratory phenomenon but rather as tools that have been shown to predict mortality in several clinical trials. It is believed that suboptimal response to an antiplatelet regimen (pharmacodynamic effect) may be associated with cardiovascular, cerebrovascular, and peripheral arterial events. There has been intense controversy about this variable response of antiplatelet drugs and the role of platelet function testing to guide antiplatelet therapy. While the importance of routine platelet function testing may be uncertain, it may be useful in high-risk patients such as those with diabetes mellitus, diffuse three vessels coronary artery disease, left main stenosis, diffuse atherosclerotic disease, and those with chronic renal failure undergoing percutaneous coronary intervention. It could also be useful in patients with suspected pharmacodynamic interaction with other drugs to assure the adequacy of platelet inhibition. While we wait for definitive trials, a predictive prognostic algorithm is necessary to individualize antiplatelet therapy with P2Y12 inhibitors based on platelet function assays and genetic testing.

Keywords: platelet function testing, platelet function assay, clopidogrel, coronary artery disease, acute coronary syndrome, coronary artery stenting

Background

The optimal use of dual antiplatelet treatment in acute coronary syndromes is evolving. While the guidelines from the American College of Cardiology and American Heart Association are largely based on population-based studies, physicians are faced with the management of individual patients who do not fit the published guidelines. Dual antiplatelet treatment has been shown to reduce the major adverse cardiovascular events after percutaneous coronary interventions (PCI), which is believed to be due to the efficacy of antiplatelet drugs.1,2 However, the response variability of patients to antiplatelet drugs, especially clopidogrel, can lead to pharmacodynamic failure, which may translate into clinical failure. The use of clopidogrel, a thienopyridine, in combination with aspirin is based on American College of Cardiology/American Heart Association guidelines on the basis of multiple trials.1,2
Dual antiplatelet therapy is recommended for 1 month after bare-metal stents and 12 months after drug-eluting stents. Premature cessation of dual antiplatelet therapy is associated with increased risk for cardiovascular events and stent thrombosis, a devastating complication.

The variable response to antiplatelet agents is well-known and has garnered more attention after several “boxed warnings” on clopidogrel. Three sequential boxed warnings on clopidogrel have led to intense controversy. There is a concern about the suboptimal response to clopidogrel, which may be due to genetic polymorphism affecting the metabolic pathways and generation of the active metabolite leading to decreased pharmacodynamic effect. However, it is not clear if the pharmacodynamic failure by platelet function assay (PFA) translates into decreased clinical efficacy. It is believed that the suboptimal response to antiplatelet regimen (pharmacodynamic effect) may be associated with cardiovascular, cerebrovascular, and peripheral arterial events. There has been intense controversy in regard to this variable response of antiplatelet drugs and the role of platelet function testing to guide antiplatelet therapy. This review will focus on the pharmacokinetic and pharmacodynamic aspects of antiplatelet drugs (thienopyridines and nonthienopyridines) and role of platelet function testing in guiding therapy.

**Pharmacokinetics of antiplatelet drugs; P2Y12 receptor antagonist**

Thienopyridine drugs, such as ticlopidine, clopidogrel, and prasugrel, and the nonthienopyridine ticagrelor bind to the P2Y12 adenosine diphosphate (ADP) receptor to initiate the clinical response. Ticlopidine, clopidogrel, and prasugrel are prodrugs that require biotransformation to active metabolites for their final effect on platelet aggregation, whereas ticagrelor does not require metabolic activation to elicit its antiplatelet effect. Ticagrelor and its active metabolites are approximately equally potent. It is well-known that clopidogrel has a substantial variability in pharmacodynamic response among 15%–40% patients.

Thienopyridines are rapidly absorbed and metabolized in the intestine and liver to generate active metabolites for the inhibition of platelet activation. These active metabolites bind to the P2Y12 receptor on the platelet leading to irreversible platelet inhibition. Ticagrelor, a nonthienopyridine, and its metabolite cause reversible platelet inhibition with equal potency. The half-life of ticagrelor is approximately 7 hours (9 hours for the active metabolite). All thienopyridines require the CYP450 system to convert the prodrugs to active metabolites, but the pathways leading to active metabolites are different. Ticagrelor, a nonthienopyridine, is mainly metabolized by CYP3A4 of the CYP450 system.

The pharmacokinetics of ticlopidine has not been well investigated. Maximum plasma concentration is reached in 1–3 hours after a single oral dose of 250 mg and steady state after 3–5 days. Ticlopidine is metabolized by at least five main pathways, leading to a minimum of 13 different metabolites, the majority of which are inactive with only one of the metabolites expressing its antiplatelet effect. A maximal level of clopidogrel active metabolite is reached in 1 hour and the plasma concentration of clopidogrel active metabolite is dose dependent up to 600 mg. Maximum concentration of the active metabolite of prasugrel is reached 30 minutes after dosing. Clopidogrel is metabolized by two different pathways. One pathway leads to 85% clopidogrel to inactive metabolite, while the remainder goes through a second pathway by two oxidation steps via CYP450 enzymes. CYP2C19 is involved in both of these steps. Since CYP2C19 is the predominant enzyme, the genetic variation in this enzyme leads to variable production of active metabolites, leading to variable response. In contrast, prasugrel undergoes a rapid de-esterification to an intermediate thioactone, which is then converted into active metabolite by a single CYP-dependent step and pharmacokinetics and pharmacodynamics are not affected by genetic variation of CYP polymorphism.

Ticagrelor and cangrelor are reversible inhibitors of P2Y12 ADP receptor and do not require metabolic activation. Ticagrelor is rapidly absorbed and undergoes enzymatic degradation to its active metabolite with maximum active metabolite and pharmacodynamic effects in 1–3 hours and plasma half-life of 7–9 hours. Cangrelor reach steady state within 30 minutes of the start of intravenous infusion. It has very short plasma half-life of 9 minutes. Elinogrel is a direct reversible P2Y12 receptor blocker. It is the first antiplatelet agent that may be administered either intravenously or orally which may facilitate a smooth transition from acute to long-term therapy. This is not approved for use in USA at the time of writing.

**Pharmacodynamics of antiplatelet drugs; P2Y12 receptor antagonist**

Platelet activation occurs with the rupture of plaque in the culprit vessel or at the implantation of coronary stents. It involves several platelet activators, including thrombin, thromboxane A2, and ADP that work through two receptors on the platelets, namely P2Y1 and P2Y12. Although the binding of ADP to both of these receptors is necessary for platelet aggregation, P2Y12 is the predominant receptor
responsible for activation and aggregation of platelets via activation of glycoprotein (GP) IIb/IIIa receptor. Binding of ADP to these P2Y12 receptors stimulates activation of GP IIb/IIIa receptors leading to enhanced platelet degranulation, thromboxane production, and platelet aggregation. Therefore, during coronary intervention, P2Y12 inhibition and inhibition of thromboxane production with acetylsalicylic acid is needed, in addition to antithrombotic regimens. Despite this dual antiplatelet therapy with acetylsalicylic acid and clopidogrel, 15%–40% of patients show poor pharmacodynamic response as determined by ADP-induced platelet aggregation.

15%–40% of patients show poor pharmacodynamic response to antiplatelet therapy with acetylsalicylic acid and clopidogrel, during coronary intervention, P2Y12 inhibition and inhibition of thromboxane production with acetylsalicylic acid is needed, in addition to antithrombotic regimens. Despite this dual antiplatelet therapy with acetylsalicylic acid and clopidogrel, 15%–40% of patients show poor pharmacodynamic response as determined by ADP-induced platelet aggregation.

Evaluation of pharmacodynamic effect by platelet function assay (PFA)

Recently, three sequential warnings, including a “boxed warning” for clopidogrel, have led to intense controversy regarding pharmacokinetic, pharmacodynamic and pharmacogenomic issues of antiplatelet drugs. These boxed warnings were concerned with the suboptimal antiplatelet effect of clopidogrel, due to its need for biotransformation by CYP450 to an active metabolite. Patients with the hypofunctioning CYP2C19 alleles have shown higher rates of cardiovascular events among those undergoing PCI in acute coronary syndromes. This warning further emphasized the need to identify such genetic polymorphism and encouraged the use of alternative antiplatelet agents. This warning followed an open label, yet to be published, study of 40 healthy volunteers, including ten individuals with varying degrees of CYP2C19 function, including poor metabolizer, intermediate metabolizer, and extensive and ultrarapid metabolizer groups. These individuals were tested with either a 300 mg loading dose and 75 mg maintenance or a 600 mg loading dose and 150 mg maintenance dose of clopidogrel. End points were concentration of active metabolite (pharmacokinetic issue) and inhibition of platelet aggregation (pharmacodynamic issue) by PFA. The main finding was decreased exposure to active metabolites and increased platelet aggregation in the poor metabolizer group compared with other groups.

PFAs

The following statement underscores the discussion regarding PFA: “Do we manage hypertension without monitoring blood pressure? Do we manage diabetes mellitus without monitoring glucose? Do we manage warfarin without monitoring INR [international normalized ratio]? So why do we use antiplatelet regimen without monitoring platelet function testing?” Unfortunately, approximately 30% of patients with acute coronary syndrome undergoing PCI and treated with clopidogrel had <30% inhibition of platelet aggregation.
Sharma et al emphasized the need of PFA to recognize such hypo- or nonresponders. Moreover, there are several studies (see Table 2) supporting the role of PFA based on outcome studies. There are many different types of PFAs, which have methodologies ranging from simple to complex. Different methods evaluating platelet function revolve around measurement of platelet aggregation, platelet reactivity, platelet receptor expression, measurement of platelet-released factors on activation, and intracellular platelet signaling. Often the question is about the extent of the ideal inhibition of platelet aggregation needed for effective clinical efficacy. While there is no standard definition of hyporesponsiveness, nonresponsiveness, or resistance to antiplatelet drugs based on platelet function testing, it is important to identify these hypo- or nonresponders to clopidogrel by PFA.

Hyporesponsiveness to clopidogrel can be secondary to several factors, including age, body mass index, diabetes, dyslipidemia, chronic renal disease, genetic polymorphism, and pharmacodynamic interaction with concomitant use of other drugs. In patients on a long-term dual antiplatelet regimen, guidelines have recommended the use of proton pump inhibitors (PPIs) to prevent gastrointestinal bleeding. However, there is an ongoing debate about the increase in major adverse cardiovascular events when PPIs are used in conjunction with clopidogrel, leading to the US Food and Drug Administration (FDA) warning that one PPI (omeprazole) reduces the antiplatelet activity of clopidogrel by 50%. Such strong pharmacodynamic interaction between clopidogrel and a PPI underscores the need for an objective test to exclude the attenuation of antiplatelet effect through the use of concomitant drugs such as omeprazole.

The role of the concurrent PPI use with clopidogrel and their effect on platelet function were assessed in analysis of Prasugrel In Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation and TRITON-TIMI 38. These trials showed that PPIs lowered the inhibition of platelet aggregation significantly in patients taking a PPI and clopidogrel simultaneously. The association between PPI use, inhibition of platelet aggregation, and clinical outcome was assessed by analysis of the Prasugrel In Comparison to Clopidogrel for Inhibition of Platelet activation and Aggregation and TRITON-TIMI 38 trials by O’Donoghue et al. In this study, no association was found between the use of PPI and clinical outcome for patients treated with clopidogrel and prasugrel. However, FDA warnings began a debate in the medical community that has often centered on the decreased efficacy of clopidogrel with concomitant use of PPIs.56

Variable platelet inhibition occurs as a result of genetic polymorphism, leading to different levels of active metabolite availability, which in turn leads to variable platelet inhibition that can be recognized by PFA. The underlying genetic variability is due to variation in alleles (nucleotides). One important and well-recognized genetic polymorphism is the CYP2C19 polymorphism. Mega et al investigated the association of CYP2C19 and plasma concentration of clopidogrel metabolite and its pharmacodynamic effect on platelet function in healthy volunteers. This association of this genetic role of CYP2C19 polymorphism translated into cardiovascular outcomes in a subgroup of 1477 patients in the trial “to assess improvement in therapeutic outcome by optimizing platelet inhibition with Prasugrel-TIMI 38.” Carriers with one hypofunctioning allele of CYP2C19 had a decreased level of clopidogrel metabolite with reduction in antiplatelet activity by platelet function testing. Consequently, there was an increased risk of cardiovascular death, acute myocardial infarction or stroke in carriers of the hypofunctioning allele of CYP2C19. Furthermore, those with the CYP2C19*2 allele had a three-fold increase of stent thrombosis. While genetic studies are important in evaluating CYP2C19 polymorphism, polymorphism of gene ABCB1, polymorphism of CYP3A4, CYP3A5, CYP2B6, or genetic polymorphism of P2Y12 receptors, the end result is a variable inhibition of platelet aggregation in response to clopidogrel. Such attenuation of the antplatelet effect of clopidogrel can be measured by PFA. While the importance of routine platelet function testing may be uncertain, it may be useful in high-risk patients such as those with diabetes mellitus, diffuse three vessels coronary artery disease, left main stenosis, diffuse atherosclerotic disease, chronic renal failure or acute coronary syndromes. Moreover, there may be suboptimal platelet inhibition in such high-risk patients due to pharmacodynamic interaction with other drugs. Multiple studies, as described below and listed in Table 2, support the argument that adequate platelet inhibition is required for thienopyridines for reducing cardiovascular events. There are several methods used to report high platelet reactivity in the clinical trials. These tests use different indices to report platelet reactivity, which include light transmittance aggregometry (LTA), VerifyNow, vasodilator-stimulated phosphoprotein (VASP), Plateletworks, Innovance PFA P2Y IMPACT R assay, and PFA-100 (as shown in Table 1).

**Outcome studies**

There are multiple small-size studies and one major outcome study (Table 2) based on PFAs. These studies examined
if suboptimal platelet inhibition translated into major cardiovascular events, using different methodologies. Gur-
bel et al investigated high platelet reactivity by LTA in elective PCI patients treated
and clot strength, a measure of thrombin-induced fibrin,
and platelet interaction by thrombelastography.60 This study
included 192 patients undergoing PCI and postclopidogrel
treatment and found that high platelet reactivity by LTA
(63% ± 12% versus 56% ± 15%) was associated with higher
ischemic events (P = 0.02). Similarly, Bliden et al reported
high platelet reactivity by LTA in elective PCI patients treated

Table 1 Platelet function assay (PFA)

<table>
<thead>
<tr>
<th>Method of PFA</th>
<th>High platelet reactivity</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTA (5 micro mol/L ADP)</td>
<td>&gt;42.9% aggregation</td>
<td>Requires dedicated lab with trained technicians; labor and time intensive</td>
</tr>
<tr>
<td>LTA (20 micro mol/L ADP)</td>
<td>&gt;64.5% aggregation</td>
<td>Requires dedicated lab with trained technicians; labor and time intensive</td>
</tr>
<tr>
<td>VerifyNow P2Y12 assay</td>
<td>&gt;236 PRU</td>
<td>Fully automated and POC and turnaround time for test is 15 minutes. VerifyNow P2Y12 Assay (Accumetrics, San Diego, California)</td>
</tr>
<tr>
<td>VASP-P</td>
<td>&gt;50 PRI</td>
<td>Requires a dedicated lab. Measures platelet reactivity index. Requires a flow cytometer</td>
</tr>
<tr>
<td>Plateletworks assay</td>
<td>&gt;80.5% aggregation</td>
<td>Semi-automated POC, time dependent; Helena Laboratories, Beaumont, Texas</td>
</tr>
<tr>
<td>PFA 100 (Collagen/ADP cartridge)</td>
<td>Closure time &lt;116 seconds</td>
<td>POC; Siemens Healthcare Diagnostic GMBH, Marburg Germany</td>
</tr>
<tr>
<td>IMPACT-R Assay</td>
<td>&gt;8.4% surface coverage</td>
<td>Extensive sample handing; Matis Medical Inc, Beersel, Belgium</td>
</tr>
<tr>
<td>With and without ADP</td>
<td>&gt;3.0% surface coverage</td>
<td></td>
</tr>
<tr>
<td>Innova P P2Y</td>
<td>&gt;299 seconds</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ADP, adenosine diphosphate; LTA, light transmittance aggregometry; POC, point of care; PRI, platelet reactivity index; PRU, P2Y12 reaction unit; VASP-P, vasodilator-stimulated phosphoprotein phosphorylation.

Table 2 Outcome studies with different inhibition of platelet aggregation

<table>
<thead>
<tr>
<th>Study</th>
<th>Study patients</th>
<th>Clopidogrel dose</th>
<th>Platelet function assay</th>
<th>Platelet reactivity measure</th>
<th>End-point prediction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matetzky et al</td>
<td>STEMI-PCI, patients: 60</td>
<td>300 mg post-PCI</td>
<td>LTA (ADP induced aggregation)</td>
<td>Patients stratified into 4 quartiles</td>
<td>MACE at 6 months P &lt; 0.01</td>
</tr>
<tr>
<td>Gurbel et al</td>
<td>ELLECTIVE PCI, patients: 192</td>
<td>300/600 mg post PCI</td>
<td>LTA and TEG</td>
<td>Patients stratified in different quartiles</td>
<td>MACE at 6 months P = 0.02</td>
</tr>
<tr>
<td>Bliden et al</td>
<td>ELLECTIVE PCI, patients: 100</td>
<td>75 mg for &gt;1 month</td>
<td>LTA and TEG</td>
<td>Pre-procedural platelet aggregation in patients on clopidogrel</td>
<td>MACE at 12 months P &lt; 0.001</td>
</tr>
<tr>
<td>Bonello et al</td>
<td>ELLECTIVE PCI, patients: 144</td>
<td>300 mg, 24 hours prior to PCI</td>
<td>VASP-P</td>
<td>PRI &gt; 50%</td>
<td>MACE at 6 months P &lt; 0.01</td>
</tr>
<tr>
<td>Price et al</td>
<td>ELLECTIVE PCI, patients: 380</td>
<td>600 mg, 12 hours prior to PCI</td>
<td>VerifyNow</td>
<td>PRU &gt; 235</td>
<td>MACE at 6 months P = 0.008</td>
</tr>
<tr>
<td>Marcucci et al</td>
<td>ACS PCI, patients: 683</td>
<td>600 mg prior to PCI</td>
<td>VerifyNow</td>
<td>PRU &gt; 240</td>
<td>MACE at 12 months CV death P = 0.034 MI P = 0.004</td>
</tr>
<tr>
<td>Migliorini et al</td>
<td>PCI unprotected LM, patients: 215</td>
<td>600 mg prior to PCI</td>
<td>LTA</td>
<td>Platelet reactivity &gt; 70%</td>
<td>MACE at 19.3 months P = 0.005</td>
</tr>
<tr>
<td>El Ghannudi et al</td>
<td>ELLECTIVE and URGENT PCI, patients: 461</td>
<td>300 or 600 mg</td>
<td>VASP-P</td>
<td>PRI &gt; 61%</td>
<td>MACE at 9 months P = 0.037</td>
</tr>
<tr>
<td>Breet et al</td>
<td>ELLECTIVE PCI, patients: 1069</td>
<td>75 mg &gt;5 days or 300 mg &gt;24 hours prior or 600 mg &gt;4 hours prior to PCI</td>
<td>LTA, VerifyNow, Plateletworks, IMPACT, Innovance PFA and PFA-100</td>
<td>Standard Platelet function measurement values</td>
<td>MACE at 12 months P values for tests shown in Figure 2</td>
</tr>
</tbody>
</table>

Abbreviations: ADP, adenosine diphosphate; LM, left main; LTA, light transmittance aggregometry; CV, cardiovascular; MACE, major adverse cardiovascular events; MI, myocardial infarction; PFA, platelet function assay; PRI, platelet reactivity index; PRU, P2Y12 reaction unit; TEG, thrombelastography; VASP-P, vasodilator-stimulated phosphoprotein phosphorylation.
Sharma et al with platelet reactivity had ischemic events ($P < 0.001$). In the other outcome study, by Migliorini, high residual platelet reactivity by LTA was evaluated in 215 consecutive patients undergoing placement of a drug-eluting stent with loading of 600 mg of clopidogrel. In that study, the primary end point was cardiac mortality and secondary end point was stent thrombosis. There was a high residual platelet reactivity in 18.6% of patients. This high residual platelet reactivity after 600 mg clopidogrel bolus was a strong marker of major cardiovascular events ($P = 0.005$).

Price et al evaluated platelet reactivity with VerifyNow assay in 380 patients undergoing elective PCI. In these patients, the high platelet reactivity was reported as P2Y12 reaction units (PRU). PRU $\geq 235$ had a significantly higher rate of cardiovascular death (2.8% versus 0%, $P = 0.008$) and a higher rate of stent thrombosis (4.6% versus 0%, $P = 0.004$) at 6 months. However, another outcome study using VerifyNow for platelet function testing involved 643 patients with acute coronary syndrome undergoing PCI. In this study, all patients received 600 mg loading of clopidogrel and major adverse cardiovascular events at 12 months (cardiovascular death; $P = 0.034$, nonfatal myocardial infarction; $P = 0.004$) was higher in patients with higher residual platelet reactivity; PRU $> 240$.

Bonello et al investigated this issue of high platelet reactivity by platelet reactivity index using VASP phosphorylation analysis. In this study, platelet reactivity predicted postprocedural major adverse cardiovascular events ($P < 0.01$) in 146 patients undergoing PCI with stents and showed a 100% negative predictive value. Similarly, the VASP test has demonstrated its predictive value for postprocedural PCI with clopidogrel in a study of 346 patients undergoing PCI with a drug-eluting stent after loading with clopidogrel using 300 mg and 600 mg.

The POPULAR (Do Platelet Function Assays Predict Clinical Outcome in Clopidogrel-Pretreated Patients Undergoing Elective PCI) study evaluated the role of higher platelet reactivity by multiple platelet function testing to predict clinical outcome. This was a prospective, observational single-center study of 1069 patients undergoing coronary stenting with clopidogrel. In this study, platelet reactivity was measured in parallel by multiple PFAs, including LTA, VerifyNow, VASP, Plateletworks, Innovance PFA P2Y IMPACT-R assay, and PFA-100, to predict primary end point of all-cause mortality, nonfatal acute myocardial infarction, stent thrombosis and ischemic stroke. This study found that PFAs, LTA, VerifyNow, Plateletworks, and Innovance PFA P2Y predicted the primary end point significantly, as illustrated in Figure 1. VASP phosphorylation analysis was not used in this comparative study.

**Discussion**

A dual antiplatelet regimen including aspirin with clopidogrel, prasugrel, or ticagrelor reduces atherothrombotic complications in patients undergoing PCI with coronary stents. Much attention has been paid to clopidogrel hyporesponsiveness after multiple FDA warnings, without consideration of aspirin hyporesponsiveness, which is a well-known phenomenon. However, individual response to dual antiplatelet regimens with clopidogrel is variable and multiple studies support the hypothesis that variable pharmacodynamic effect may be responsible for atherothrombotic events. Moreover, hyporesponsiveness to clopidogrel has been found to be an independent predictor of cardiovascular events in patients with ACS undergoing percutaneous interventions, especially in patients with CYP2C19 genetic polymorphism. A major drawback of these studies has been small sample sizes with evaluation of platelet function by a single assay, as described in Table 2. The popular "Do Platelet Function Assays Predict Clinical Outcome in Clopidogrel-Pretreated Patients Undergoing Elective PCI" trial evaluated the ability of multiple PFAs in the prediction of atherothrombotic events. This study showed that several PFAs, including LTA, VerifyNow, Plateletworks, and Innovance PFA, predicted cardiovascular events, as shown in Figure 1. Several points of care systems have become available to assess inhibition of aggregation (Table 1). One of the commonly used tests in several previous studies and ongoing studies is VerifyNow. This point-of-care PFA correlated well with LTA, which is considered the gold standard. It is relatively inexpensive and easy to perform with excellent reproducibility. Several studies (Table 2) have shown higher ischemic event rates with suboptimal platelet inhibition with VerifyNow reported as PRU $> 230$ or high platelet reactivity measured by LTA.

Thienopyridines or nonthienopyridines, such as ticagrelor, inhibit platelet activation via the P2Y12 ADP receptor and the extent of this inhibition is reported as PRU units by VerifyNow. The VerifyNow assay uses ADP and PGE1 to determine platelet reactivity mediated through ADP receptors and a separate channel using thrombin receptors to estimate uninhibited response. This test takes advantage of different receptors of platelet stimulated by different agonists. Thrombin receptors are strong platelet activators and function independent of P2Y12 ADP receptors. Therefore,
the base value (base PRU) is calculated by stimulating these receptors to estimate the total possible platelet aggregation, as if the patient had never received clopidogrel even in the presence of clopidogrel. Then, the extent of platelet inhibition by clopidogrel can be measured by using selective ADP agonist to measure P2Y12 ADP receptor inhibition by thienopyridines or nonthienopyridines. The percent inhibition of P2Y12 ADP receptors is determined by the difference between base PRU and PRU determined from ADP agonist.52 However, one needs to understand that the values of the absolute PRU is calculated by ADP agonist; base PRU by thrombin agonist; and percent inhibition on the difference.
of both. It is better to follow the absolute PRU rather than the per cent P2Y12 inhibition, as the calculated per cent P2Y12 inhibition is derived from value obtained from using two different agonists, making a valid comparison difficult.

The PFA to guide and tailor antiplatelet therapy has received considerable attention. One of the major limitations in this field is the lack of definitions for hyporesponder and nonresponder. Tailored antiplatelet therapy is meant to achieve adequate platelet inhibition guided by PFAs. This is an important issue for the possibility of using more potent antiplatelet drugs, like prasugrel and ticagrelor, in patients who are hyporesponders or nonresponders to clopidogrel. Moreover, PFAs may be useful to monitor triple antiplatelet therapy with adjunctive use of cilostazol\(^71\) or adjunctive use of omega-3 fatty acids.\(^72\)

### Algorithm to address issue of hyporesponders or nonresponders to clopidogrel

Physicians must be aware that genetic factors and nongenetic factors alter clopidogrel metabolism leading to variable inhibition of platelet aggregation. This has been shown to translate into adverse outcomes in clinical trials as discussed above. At the present time, the evidence base is insufficient to recommend routine platelet function testing or routine genetic testing. However clinical judgment is required to assess higher clinical and angiographic risk factors where being a hyporesponder to clopidogrel may lead to a poor outcome and tailored antiplatelet therapy or alternative antiplatelet agent such as prasugrel or ticagrelor may be considered. While there is no expert consensus on routine platelet function testing or genetic testing, certain guidelines have been proposed in high-risk patients with clinical conditions such as diabetes mellitus, diffuse three vessels coronary artery disease, left main stenosis, diffuse atherosclerotic disease or chronic renal failure.\(^59\) In these patients, an expert panel recommends that platelet function testing or genetic testing may be considered to identify and adequately treat clopidogrel hyporesponder.\(^73,74\)

Due to concern over mortality and morbidity which may be attributable to the suboptimal response to antiplatelet therapy, there are several alternative approaches to standard guidelines. New antiplatelet agents such as prasugrel and

---

**Figure 2** Algorithm based on pharmacodynamic concepts.

**Notes:** *Contraindicated in patient with history of stroke and TIA. **High-dose clopidogrel option; 600 mg loading and 150 mg daily, guided by platelet function assay. ***Diabetes mellitus, left main stenosis, diffuse atherosclerotic disease, chronic renal failure, and acute coronary syndromes.  
**Abbreviations:** TIA, transient ischemic attack; ACS, acute coronary syndromes; PCI, percutaneous coronary intervention; DM, diabetes mellitus; LM, left main; CAD, coronary artery disease.
ticagrelor have demonstrated superiority in patients with acute coronary syndrome.\textsuperscript{53,68} These new drugs are not affected by CYP2C19 genetic variants and are more effective, with a more predictable pharmacodynamic response than the standard dose of clopidogrel. While the ongoing trials will expand our understanding of dual antiplatelet regimens and the role of PFA, use of point of care testing to guide treatment in possible hyporesponders or nonresponders to antiplatelet regimen may be useful. At this time, routine clinical use of PFAs to maximize efficacy in PCI cannot be recommended, but for selected patients it may be wise to consider PFAs such as diabetes, multi vessel coronary artery disease, bifurcation stenosis, left main disease or acute coronary syndromes as illustrated in Figure 2 and Figure 3 below. A predictive prognostic algorithm is necessary to individualize antiplatelet therapy with P2Y12 inhibitors based on PFAs and genetic testing. While we wait for definitive trials, the following algorithm may be useful (Figures 2 and 3).

![Algorithm based on pharmacodynamic concept](https://www.dovepress.com/)

**Figure 3** Algorithm based on pharmacodynamic concept.

**Notes:** *Diabetes mellitus, left main stenosis, diffuse atherosclerotic disease, chronic renal failure and acute coronary syndromes. **Avoid in patients aged $>75$ years or weighing $<60$ kg, contraindicated in patients with history of TIA or stroke. ***High-dose clopidogrel option: 600 mg loading and 150 mg daily, guided by PFA.

**Abbreviations:** IPA, inhibition of platelet aggregation; PFA, platelet function assay; PRU, P2Y12 reaction units; TIA, transient ischemic attack.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


